Prosecution Insights
Last updated: August 18, 2026
Application No. 18/870,026

HAIR TREATMENT METHOD FOR LIMITING THE CALCIUM CONTENT OF THE HAIR

Non-Final OA §112§DP
Filed
Nov 27, 2024
Priority
Jun 01, 2022 — FR FR2205265 +1 more
Examiner
DAVIS, BRIAN J
Art Unit
Tech Center
Assignee
L'Oréal
OA Round
1 (Non-Final)
85%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
81%
With Interview

Examiner Intelligence

Grants 85% — above average
85%
Career Allowance Rate
1341 granted / 1581 resolved
+24.8% vs TC avg
Minimal -4% lift
Without
With
+-4.1%
Interview Lift
resolved cases with interview
Fast prosecutor
1y 9m
Avg Prosecution
46 currently pending
Career history
1618
Total Applications
across all art units

Statute-Specific Performance

§101
5.2%
-34.8% vs TC avg
§103
16.5%
-23.5% vs TC avg
§102
19.5%
-20.5% vs TC avg
§112
44.7%
+4.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1581 resolved cases

Office Action

§112 §DP
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Information Disclosure Statement The lined-through patent is drawn to a tension-relieving device – i.e. clearly not germane to the instant invention. The lined-through NPL reference is an entire standard reference text. (Note 37 CFR 1.98(b)(5) “Each publication listed in an information disclosure statement must be identified by publisher, author (if any), title, relevant pages of the publication [emphasis added], date, and place of publication.”) Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 30 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. There is insufficient antecedent basis for the limitation “…wherein the (vii) one or more non-ionic polysaccharides…” in the claim. The examiner respectfully suggests that the claim should properly depend from claim 29 (not claim 28). Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claim 34 is provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claim 34 of copending Application No. 18/870,019 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other. The instant claim and that of the reference application are virtually identical. The only differences being: (a) the preamble of the instant claim describes the method as a method for limiting calcium amount in the hair, while the reference application claim describes the method as a method for treating keratin fibers – although the steps of each method are essentially the same; (b) the reference application claim explicitly teaches a step of rinsing after a leave-on time – however, such a step is intrinsic to the method of the instant method (because the purpose of the instant method is to remove calcium from the hair, there must be such a step); finally, the instant claim teaches that the one or more hydroxylated (poly)carboxylic acids are present in at least 0.5% by weight of the total composition, while the reference application claim teaches at least 3% by weight - which is encompassed. This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. Allowable Subject Matter Claims 1-29, 31-33, and 35-37 are allowed. The subject matter of claim 30 would be allowable once the 112 rejection outlined above has been overcome. The following is a statement of reasons for the indication of allowable subject matter: US 5,635,167 appears to be the closest prior art. The reference teaches a method of removing minerals from human hair, and animal keratin fibers, utilizing a composition comprising a chelating agent which may be an amino acid agent of formula (I) (or a polyphosphate-type agent, or a phosphate-type agent) (abstract; column 4, line 65ff). The amino acid agents perform the best (column 4, line 65). These amino acids of prior art formula (I) are not those of the instant amino acid agents of formula (I). Blend compositions of the prior art chelating agents have been designed for the synergistic and complete removal of a wide range of minerals adsorbed on keratin fibers such as hair, wool and feathers (column 9, line 61). Citric acid (a hydroxylated (poly)carboxylic acid) is added as a pH adjuster to exemplified compositions (column 9, line 65; column 10, line 1; column 10, TABLE 5). In short, the cited art does not teach, show, suggest or make obvious the instant methods. Conclusion The prior art made of record and not relied upon is considered pertinent to applicant's disclosure: US 5,804,172 and US 2018/0000706 A1 are cited to show related compositions and methods for removing minerals from hair. Any inquiry concerning this communication or earlier communications from the examiner should be directed to BRIAN J DAVIS whose telephone number is (571)272-0638. The examiner can normally be reached M-F 8:30-5:00 PM EDT. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Ali Soroush, can be reached at 571-272-9925. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /BRIAN J DAVIS/Primary Examiner, Art Unit 1614 7/18/2026
Read full office action

Prosecution Timeline

Nov 27, 2024
Application Filed
Jul 22, 2026
Non-Final Rejection mailed — §112, §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12703696
Diacylglycerol Acyl Transferase 2 Inhibitors
2y 8m to grant Granted Aug 11, 2026
Patent 12702661
METHODS OF TREATMENT OF TUBEROUS SCLEROSIS COMPLEX
2y 3m to grant Granted Aug 11, 2026
Patent 12697333
Methods of Treating Splenomegaly
4y 7m to grant Granted Aug 04, 2026
Patent 12691100
NOVEL USE
4y 2m to grant Granted Jul 28, 2026
Patent 12678516
IMMUNOSTIMULATORY TOLL-LIKE RECEPTOR AGONIST-NANOPARTICLE FOR CANCER IMMUNOTHERAPY
2y 9m to grant Granted Jul 14, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
85%
Grant Probability
81%
With Interview (-4.1%)
1y 9m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1581 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month